// App-Quantinova.ai

POS0853 (2022) : EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD)

Researchers

Presenter

  • S. Assassi

Principal Investigators

  • M. Kuwana

  • C. P. Denton

  • T. Maher

  • C. Diefenbach

  • C. Ittrich

  • M. Gahlemann

  • O. Distler

Medical Centers

  • University of Texas McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, United States of America

  • Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Tokyo, Japan

  • Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom

  • University of Southern California Keck School of Medicine, Los Angeles, California, United States

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine and Clinical Pharmacology, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim (Schweiz), GmbH, Basel, Switzerland,

  • University Hospital Zurich, University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland

Locations

  • United States

  • Japan

  • United Kingdom

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved